Gastric carcinoids (GCs), which originate from gastric enterochromaffin-like (ECL) mucosal cells and account for 2.4% of all carcinoids, are found increasingly in the course of upper gastrointestinal tract endoscopy. Current nosography includes those occurring in chronic conditions with hypergastrinemia, as the type 1 associated with chronic atrophic gastritis, and the type 2 associated with Zollinger-Ellison syndrome in multiple endocrine neoplasia type 1, and type 3, which is unrelated to hypergastrinemia and is frequently malignant, with distant metastases. The optimal clinical approach to GCs remains to be elucidated, depending upon type, size and number of carcinoids. While there is agreement concerning the treatment of type 3 carcinoids, for types 1 and 2, current possibilities include simple surveillance, endoscopic polypectomy, surgical excision, associated or not with surgical antrectomy, or total gastrectomy. Moreover, the recent introduction of somatostatin analogues represents a therapeutic option of possibly outstanding relevance.

Gastric carcinoids : between underestimation and overtreatment / S. Massironi, V. Sciola, M.P. Spampatti, M. Peracchi, D. Conte. - In: WORLD JOURNAL OF GASTROENTEROLOGY. - ISSN 1007-9327. - 15:18(2009 May), pp. 2177-2183.

Gastric carcinoids : between underestimation and overtreatment

S. Massironi
Primo
;
V. Sciola
Secondo
;
M. Peracchi
Penultimo
;
D. Conte
Ultimo
2009

Abstract

Gastric carcinoids (GCs), which originate from gastric enterochromaffin-like (ECL) mucosal cells and account for 2.4% of all carcinoids, are found increasingly in the course of upper gastrointestinal tract endoscopy. Current nosography includes those occurring in chronic conditions with hypergastrinemia, as the type 1 associated with chronic atrophic gastritis, and the type 2 associated with Zollinger-Ellison syndrome in multiple endocrine neoplasia type 1, and type 3, which is unrelated to hypergastrinemia and is frequently malignant, with distant metastases. The optimal clinical approach to GCs remains to be elucidated, depending upon type, size and number of carcinoids. While there is agreement concerning the treatment of type 3 carcinoids, for types 1 and 2, current possibilities include simple surveillance, endoscopic polypectomy, surgical excision, associated or not with surgical antrectomy, or total gastrectomy. Moreover, the recent introduction of somatostatin analogues represents a therapeutic option of possibly outstanding relevance.
Chronic atrophic gastritis; Endocrine tumors; Enterochromaffin-like cells; Gastric carcinoids; Hypergastrinemia; Multiple endocrine neoplasia tupe 1; Well-differentiated tumors; Zollinger-Ellison syndrome
Settore MED/12 - Gastroenterologia
mag-2009
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/71066
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 27
social impact